July 31, 2018, Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (CSE: VP, FSE: 1JV1) (“Vodis” or the “Company”) announces it intends to raise gross proceeds of up to $2,000,000 through a non-brokered private placement financing of up to 20,000,000 units (the "Units") of the Company at a price of $0.10 per Unit. Each Unit will consist of one common share and one common share purchase warrant (a "Warrant"), whereby each Warrant will entitle the holder to purchase one common share in the capital of the Company (a “Warrant Share”) for a period of five years from the date of issuance at an exercise price of $0.15 per Warrant Share.
The non-brokered private placement financing is subject to all necessary regulatory approvals and the securities to be issued in connection with the private placement financing will be subject to a four-month hold period in accordance with applicable Canadian securities laws. Vodis intends to use the net proceeds to complete rooms at the issuer’s facilities in Bellingham, complete upgrades at its Delta facility to meet Health Canada licence requirements, equipment purchases, payment of taxes and to fund working capital needs during the licensing phase and production phase.
The Company also announces the resignation, effective July 29, 2018, of John Bean as a director of Vodis. The Company extends its gratitude to John Bean for assistance he has provided since his appointment as a director and wishes him well in his future endeavors.
About Vodis Pharmaceuticals Inc.
Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.
While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State licence holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand quality standards.
For further information please contact:
Ivan Miliovski, Chief Executive Officer
Vodis Pharmaceuticals Inc.
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
This news release contains “forward-looking information” within the meaning of applicable securities laws including statements relating to the outlook of the business of the Company, the Company’s intention to complete the private placement financing, the potential granting of a cultivation licence by Health Canada, and planned expenditures for upgrades and other renovations at the Company’s Delta, BC, and Washington facilities. Although the Company believes considering the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them as the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements, depending on, among other things, the risks that the private placement financing may not close for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities) or that the terms of the private placement financing may differ from those that currently are contemplated. The statements in this news release are made as of the date of this release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
- Page 1 of 73